SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

Pasatru

REGN·Regeneron Pharmaceuticals, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially launched as of August 19, 2026.
Why 4/10
Pasatru was FDA-approved on August 19, 2026, so the defining binary catalyst has passed. No new PDUFA or pivotal readout is scheduled in the next ~12 months; the planned OPTIMA 2 pediatric Phase 3 trial start is not a hard binary catalyst. As a small part of Regeneron's large pipeline (~$89B market cap, $4.3B quarterly revenue), Pasatru alone cannot drive a major share-price move, so impactScore is 4.
Actionable Insight NEUTRAL

Pasatru is already approved and launching commercially; the next catalyst is the start of the Phase 3 OPTIMA 2 pediatric/adolescent trial (planned for later 2026), which would expand the addressable population but is not a binary event. Watch Q3 2026 earnings (today, Oct 30) for initial Pasatru sales commentary and any updates on OPTIMA 2 enrollment timing. For a company with ~$89B market cap and $4.3B quarterly revenue, Pasatru is a small but strategically important rare-disease franchise builder.

Price Chart

Loading chart...

Executive Summary

Pasatru (garetosmab-grts) is Regeneron's FDA-approved monoclonal antibody for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder affecting roughly 900 US patients. Approved on August 19, 2026 via Priority Review, it is the first and only treatment that reduces both new abnormal bone formation and flare-ups in adults with FOP. The Phase 3 OPTIMA trial showed a 90%+ reduction in new bone lesions at 56 weeks, and 84-week extension data (presented October 2026 at ASBMR and published in The Lancet) showed zero new lesions from week 56 to 84. Annual list pricing ranges from $693,000 to $2.1 million depending on dose and patient weight. For Regeneron, a large-cap biotech with ~$89B market cap and blockbuster products like Eylea and Dupixent, Pasatru represents a small but strategically important entry into rare disease, though it is unlikely to materially move the stock on its own.

How It Works

Pasatru is a lab-made antibody (a type of protein) that blocks a signaling molecule called activin A. In people with FOP (sometimes called 'stone man disease'), a genetic mutation causes activin A to trigger bone growth in muscles, tendons and ligaments where bone should not form. By neutralizing activin A, Pasatru prevents this abnormal bone formation and reduces painful flare-ups. It is given as a one-hour intravenous infusion once every four weeks.

Trial Status

The Phase 3 OPTIMA trial (56-week placebo-controlled + 84-week open-label extension) in adults with FOP is complete with positive results published in The Lancet. A separate Phase 3 trial in pediatric/adolescent patients (OPTIMA 2) is planned to begin later in 2026 but has not yet started recruiting.

The Two-Sided Case

▲ Bull Case1
First and only FDA-approved treatment that reduces both new heterotopic ossification lesions AND flare-ups in adult FOP, offering a differentiated mechanism vs oral competitor Sohonos. Phase 3 OPTIMA data showed zero new HO lesions from weeks 56 to 84 in the extension, demonstrating sustained disease control. The 84-week results were published in The Lancet (October 2026) and presented at ASBMR, adding strong peer-reviewed evidence. Annual pricing of $693K-$2.1M per patient positions Pasatru as a high-value ultra-orphan drug, and the planned OPTIMA 2 pediatric trial could expand the addressable population. Multiple analyst upgrades and price target raises in Q4 2026 reflect growing confidence in Regeneron's pipeline.
▼ Bear Case1
Ultra-rare FOP affects only ~900 US patients, capping peak sales potential even at high pricing. Competition from Ipsen's Sohonos (palovarotene, oral) and Atebrioz creates a three-way market for a tiny patient pool. Skin and soft tissue infections (abscesses, cellulitis) occurred in 65% of patients on the 10 mg/kg dose vs 33% on placebo, a safety signal that could limit uptake. At ~$1.4M average annual list price, payer access and reimbursement hurdles are significant for an ultra-orphan infused biologic. Pasatru is a tiny fraction of Regeneron's ~$17B+ annual revenue, so even strong sales would have minimal impact on the stock.

Upcoming Catalysts

  • OPTIMA 2 Phase 3 trial initiation in pediatric/adolescent FOP patients (planned later 2026)
  • Initial Pasatru sales commentary on Regeneron Q3 2026 earnings call (October 30, 2026)
  • Potential European Medicines Agency (EMA) filing for EU approval

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Regeneron Pharmaceuticals, Inc. PRESS-RELEASE REGN ·Originating report

Sources · 10

Hover a chip for the title
1 investor.regeneron.com2 investor.regeneron.com3 accessdata.fda.gov4 regeneron.com5 drugs.com6 pharmadossier.com7 ifopa.org8 managedhealthcareexecutive.com9 unibestpharm.com10 pasatruhcp.com